ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
76 hedge funds and large institutions have $150M invested in Adaptimmune Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
41% less capital invested
Capital invested by funds: $256M → $150M (-$106M)
Holders
76
Holding in Top 10
1
Calls
$132K
Puts
$35K
Top Buyers
| 1 | +$1.62M | |
| 2 | +$385K | |
| 3 | +$292K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$181K |
| 5 |
JPMorgan Chase & Co
New York
|
+$119K |
Top Sellers
| 1 | -$8.23M | |
| 2 | -$1.07M | |
| 3 | -$705K | |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$585K |
| 5 |
HCA
Harbor Capital Advisors
Chicago,
Illinois
|
-$297K |